Category: Regulatory DisclosuresBy adminJune 15, 2022 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:Disclosure to EGX on BOD minutesNextNext post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. acquires a fast-growing anticonvulsant which grew at 2019-21 CAGR of 226%Related PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
